These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38928347)

  • 41. Prognostic impact of orotate phosphoribosyl transferase among 5-fluorouracil metabolic enzymes in resectable colorectal cancers treated by oral 5-fluorouracil-based adjuvant chemotherapy.
    Ochiai T; Nishimura K; Noguchi H; Kitajima M; Tsukada A; Watanabe E; Nagaoka I; Futagawa S
    Int J Cancer; 2006 Jun; 118(12):3084-8. PubMed ID: 16425285
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adjuvant therapy after resection of colorectal liver metastases: the predictive value of the MSKCC clinical risk score in the era of modern chemotherapy.
    Rahbari NN; Reissfelder C; Schulze-Bergkamen H; Jäger D; Büchler MW; Weitz J; Koch M
    BMC Cancer; 2014 Mar; 14():174. PubMed ID: 24612620
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of Cathepsin S as a marker of prognosis and predictor of chemotherapy benefit in adjuvant CRC: a pilot study.
    Gormley JA; Hegarty SM; O'Grady A; Stevenson MR; Burden RE; Barrett HL; Scott CJ; Johnston JA; Wilson RH; Kay EW; Johnston PG; Olwill SA
    Br J Cancer; 2011 Nov; 105(10):1487-94. PubMed ID: 21989182
    [TBL] [Abstract][Full Text] [Related]  

  • 44. MiR-320e is a novel prognostic biomarker in colorectal cancer.
    Perez-Carbonell L; Sinicrope FA; Alberts SR; Oberg AL; Balaguer F; Castells A; Boland CR; Goel A
    Br J Cancer; 2015 Jun; 113(1):83-90. PubMed ID: 26035698
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment.
    Dotor E; Cuatrecases M; Martínez-Iniesta M; Navarro M; Vilardell F; Guinó E; Pareja L; Figueras A; Molleví DG; Serrano T; de Oca J; Peinado MA; Moreno V; Germà JR; Capellá G; Villanueva A
    J Clin Oncol; 2006 Apr; 24(10):1603-11. PubMed ID: 16575011
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Differential clinical benefits of 5-fluorouracil-based adjuvant chemotherapy for patients with stage III colorectal cancer according to CD133 expression status.
    Shikina A; Shinto E; Hashiguchi Y; Ueno H; Naito Y; Okamoto K; Kubo T; Fukazawa S; Yamamoto J; Hase K
    Jpn J Clin Oncol; 2014 Jan; 44(1):42-8. PubMed ID: 24244031
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer.
    Stoehlmacher J; Park DJ; Zhang W; Yang D; Groshen S; Zahedy S; Lenz HJ
    Br J Cancer; 2004 Jul; 91(2):344-54. PubMed ID: 15213713
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic impact of orotate phosphoribosyl transferase activity in resectable colorectal cancers treated by 5-fluorouracil-based adjuvant chemotherapy.
    Ochiai T; Nishimura K; Noguchi H; Kitajima M; Tsuruoka Y; Takahashi Y; Tsukada A; Watanabe E; Nagaoka I; Futagawa S
    J Surg Oncol; 2006 Jul; 94(1):45-50. PubMed ID: 16788943
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A retrospective analysis using deep-learning models for prediction of survival outcome and benefit of adjuvant chemotherapy in stage II/III colorectal cancer.
    Li X; Jonnagaddala J; Yang S; Zhang H; Xu XS
    J Cancer Res Clin Oncol; 2022 Aug; 148(8):1955-1963. PubMed ID: 35332389
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combinations of single nucleotide polymorphisms WWOX-rs13338697, GALNT14-rs9679162 and rs6025211 effectively stratify outcomes of chemotherapy in advanced hepatocellular carcinoma.
    Lin WR; Hsu CW; Yeh CS; Chen YC; Chang ML; Liang KH; Lin CC; Chu YD; Yeh CT
    Asia Pac J Clin Oncol; 2018 Apr; 14(2):e54-e63. PubMed ID: 28695683
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Influence of thymidylate synthase DNA polymorphisms and gender on the clinical evolution of patients with advanced colorectal cancer.
    Fernández-Contreras ME; Sánchez-Hernández JJ; Guijarro M; Gisbert JP; Rivas N; García de Paredes ML; Hinojar-Gutiérrez A; Gamallo C
    Oncol Rep; 2010 May; 23(5):1393-400. PubMed ID: 20372856
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Decreased expression of PinX1 protein predicts poor prognosis of colorectal cancer patients receiving 5-FU adjuvant chemotherapy.
    Deng W; Jiao N; Li N; Wan X; Luo S; Zhang Y
    Biomed Pharmacother; 2015 Jul; 73():1-5. PubMed ID: 26211574
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Upregulation of HOXA10 Protein Expression Predicts Poor Prognosis for Colorectal Cancer.
    Yuan Y; Sun S; Jiao N; Shu Y; Zhang Y
    Genet Test Mol Biomarkers; 2018 Jun; 22(6):390-397. PubMed ID: 29870276
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Chidharla A; Rapoport E; Agarwal K; Madala S; Linares B; Sun W; Chakrabarti S; Kasi A
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373376
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Expression of astrocyte-elevated gene-1 indicates prognostic value of fluoropyrimidine-based adjuvant chemotherapy in resectable stage III colorectal cancer.
    Lin LW; Lai PS; Chen YY; Chen CY
    Pathol Int; 2021 Nov; 71(11):752-764. PubMed ID: 34528330
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy.
    Yamada H; Iinuma H; Watanabe T
    Oncol Rep; 2008 Mar; 19(3):729-35. PubMed ID: 18288408
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A single nucleotide polymorphism on the GALNT14 gene as an effective predictor of response to chemotherapy in advanced hepatocellular carcinoma.
    Yeh CT; Liang KH; Lin CC; Chang ML; Hsu CL; Hung CF
    Int J Cancer; 2014 Mar; 134(5):1214-24. PubMed ID: 23959947
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Predictive nomogram of the clinical outcomes of colorectal cancer based on methylated SEPT9 and intratumoral IL-10
    Sun J; Shi S; Sun C; Wang J; Yang X; Yang Z; Xu J; Zhang S
    J Transl Med; 2024 Sep; 22(1):861. PubMed ID: 39334238
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy of Adjuvant 5-Fluorouracil Therapy for Patients with EMAST-Positive Stage II/III Colorectal Cancer.
    Hamaya Y; Guarinos C; Tseng-Rogenski SS; Iwaizumi M; Das R; Jover R; Castells A; Llor X; Andreu M; Carethers JM
    PLoS One; 2015; 10(5):e0127591. PubMed ID: 25996601
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic significance of MUC2, CDX2 and SOX2 in stage II colorectal cancer patients.
    Ribeirinho-Soares S; Pádua D; Amaral AL; Valentini E; Azevedo D; Marques C; Barros R; Macedo F; Mesquita P; Almeida R
    BMC Cancer; 2021 Apr; 21(1):359. PubMed ID: 33823840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.